Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides [PDF]
Frontiers in Cardiovascular Medicine, 2021 This review summarizes current knowledge regarding clinical epidemiology, pathophysiology, and prognosis for patients with HFmrEF in comparison to HFrEF and HFpEF. Although recommended treatments currently focus on aggressive management of comorbidities,
Kaiyuan Zhu +8 more
doaj +2 more sources
Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction [PDF]
Frontiers in Cardiovascular Medicine, 2021 Pulmonary hypertension (PH) is common in patients with heart failure (HF). The role of PH in patients with HF with reduced (HFrEF) and preserved (HFpEF) left ventricular ejection fraction (LVEF) has been extensively characterized during the last years ...
Micha T. Maeder +5 more
doaj +2 more sources
Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines [PDF]
ESC Heart Failure, 2020 Currently, the assessment of left ventricular ejection fraction (LVEF) is the cornerstone of the classification of patients with heart failure (HF). The mid‐range LVEF (HFmrEF) category was identified in an attempt to uncover specific characteristics of ...
Luca Branca +3 more
doaj +2 more sources
Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage? [PDF]
Frontiers in Cardiovascular Medicine, 2021 Heart failure with mid-range ejection fraction (HFmrEF) was first proposed by Lam and Solomon in 2014, and was listed as a new subtype of heart failure (HF) in 2016 European Society of Cardiology guidelines. Since then, HFmrEF has attracted an increasing
Qing Zhou +18 more
doaj +2 more sources
Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction [PDF]
ESC Heart Failure, 2020 Aims Heart failure with mid‐range ejection fraction (HFmrEF) has been proposed as a distinct HF phenotype, but whether patients on this category fare worse, similarly, or better than those with HF with reduced EF (HFrEF) or preserved EF (HFpEF) in terms ...
Enrique Santas +9 more
doaj +2 more sources
Treatment of Heart Failure With Mid-Range Ejection Fraction: A Summary of Current Evidence [PDF]
Frontiers in Cardiovascular Medicine, 2021 Heart failure (HF) is a complex syndrome causing heavy burden in public health, and the modern objective assessment of it is based on the left ventricular ejection fraction (LVEF). In 2016, the European Society of Cardiology classified the “gray area” in
Teng Ma, Yang Su, Jing Song, Dachun Xu
doaj +2 more sources
Heart Failure with Mid-Range Ejection Fraction - State of the Art [PDF]
Arquivos Brasileiros de Cardiologia, 2019 In 2016, the European Society of Cardiology (ESC) recognized heart failure (HF) with ejection fraction between 40 and 49% as a new HF phenotype, HF with mid-range ejection fraction (HFmrEF), with the main purpose of encouraging studies on this new ...
Evandro Tinoco Mesquita +2 more
doaj +2 more sources
Use of angiotensin receptor blocker is associated with improved 1 year mortality in heart failure with mid‐range ejection fraction [PDF]
ESC Heart Failure, 2021 Aims Current evidence about the effect of angiotensin receptor blocker (ARB) on the outcome of heart failure with mid‐range ejection fraction (HFmrEF) is lacking.
Bin Wang +6 more
doaj +2 more sources
Long‐term mortality in heart failure with mid‐range ejection fraction: systematic review and meta‐analysis [PDF]
ESC Heart Failure, 2022 Aims Heart failure patients with mid‐range ejection fraction (HFmrEF) have overlapping clinical features, compared with patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).
Deep Chandh Raja +10 more
doaj +2 more sources
Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction [PDF]
ESC Heart Failure, 2020 Aims Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients ...
Nobuyuki Enzan +6 more
doaj +2 more sources